EDCTP Programme Overview - Education.gouv.fr · • Established as a flagship European–Africa partnership and recognised international funder on clinical research for PRNIDs •

EDCTP Programme Overview

Michael Makanga, MD PhD FRCP Edin

EDCTP Events Day, Paris, 30 June 2017

The European & Developing Countries Clinical Trials

Partnership (EDCTP) is a public-public partnership

between institutions mandated by national

governments in Europe and sub-Saharan Africa, and

supported by the European Union.

Who we are

EDCTP public-public partnership

14 European Countries

Austria, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, Netherlands, Norway, Portugal, Spain, Sweden and United Kingdom

1 Aspirant Member

Switzerland

14 African Countries

Burkina Faso, Cameroon, Rep of Congo, Gabon, Ghana, Mali, Mozambique, Niger, Senegal, South Africa, Tanzania, The Gambia, Uganda, Zambia

EDCTP: North-South Collaborative Programme

To reduce poverty in SSA through improved health by funding collaborative research to enhance research

capacity and accelerate the development of new or improved medical interventions against PRNDs.

Targets and bench marks for each indicator

Performance indicators

Expected results in measurable terms (outputs/outcomes)

Increase new or

improved

medical

interventions

against PRNDs

Increase Cooperation

with SSA

through capacity

building (CTs,

Ethics &

Regulatory)

Improve coordination

alignment and

integration of

European

National

Programmes

Increase

International

Cooperation

with third

parties

Increase

interaction with

Development

partners

(incl.EU and

WHO

initiatives)

Mission

Focus Cooperation Excellence Integrity Transparency Respect

To reduce the social and economic

burden of PRNDs in SSA Vision

(overall goal)

Mission

Specific

objectives

(Pillars)

Implementation:

RBM Approach

Values

(Anchors)

• Established as a flagship European–Africa partnership and recognised international

funder on clinical research for PRNIDs

• Operates as a true ‘partnership of equals’ between North and South, with input from

both European and African countries at all levels

• Promotes development of sustainable capacity of sub-Saharan Africa countries to

conduct clinical studies

• Encompasses target populations often excluded from clinical studies but with major

unmet medical needs

• Programme expansion covers implementation research on delivery and uptake of

medical research makes its work even more relevant to health services in sub-Saharan

Africa countries

• Focus on clinical challenges and policy-relevant questions, ensuring the results of

research feed directly into national and international policy-making

• Commitment to working with like-minded partners, to take advantage of the

platform established for high-quality research.

Key features of EDCTP

The EDCTP funding programme

How we work

• Coordination of European national programmes

• Equal partnership with sub-Saharan Africa

• Synergy among R&D actors

• Accelerate the development of interventions to fight

PRNIDs

• Support of capacity development and networking

Private sector

Product Development

Partnerships

Research institutions

International Organisations

Development assistance &

cooperation

Target diseases

* Based on the WHO list of neglected tropical diseases (excluding Chagas disease)

• HIV, tuberculosis, malaria

• Neglected infectious diseases*

Buruli ulcer; Chikungunya; Dengue; Dracunculiasis (guinea-worm

disease); Echinococcosis; Foodborne trematodiases; Human African

trypanosomiasis (sleeping sickness); Leishmaniasis; Leprosy (Hansen’s

disease); Lymphatic filariasis; Mycetoma; Onchocerciasis (river blindness);

Rabies; Schistosomiasis; Soil-transmitted helminthiases;

Taeniasis/Cysticercosis; Trachoma; Yaws (Endemic treponematoses)

• Diarrhoeal diseases

• Lower respiratory tract infections

• Emerging and re-emerging infectious diseases of particular relevance

for Africa, such as Ebola virus disease and yellow fever.

Vulnerable populations

• Pregnant women

• Newborns

• Children and adolescents

• People living with co-infections

and co-morbidities

Low interventional clinical trials

Clinical trial on

specific populations

Clinical trials

Clinical studies supported by EDCTP

Discovery &

Pre-clinical

research Phase I Phase II Phase III Phase IV

Human

pharmacology

Safety and/or

efficacy of

investigational

medicinal

product

product

formulation,

dosing

recommendations

Biomarkers,

Pharmacogenomics

Pragmatic trials

Implementation

research

Product focused

implementation research

Effectiveness

Comparing medical

intervention strategies

Optimizing the use of

existing intervention

Diagnostics test validation

Therapeutic use Therapeutic

exploratory

Therapeutic

confirmatory

EDCTP programme

implementation:

integrated

approach

Eligibility criteria for EDCTP calls for

proposals

Research & Innovation

Actions (RIA)

Coordination & Support

Actions (CSA)

Training & Mobility

Actions (TMA)

Consortia of ≥ 2 European

countries and ≥ 1 sub-

Saharan African country

Individual institutions or

consortia for ethics,

training, networking and

regulatory activities

Grants to individuals:

Career development,

Senior, other

Either full funding (RIA)

(100% of costs) or

cofunding (SRIA) (≤50%)

with other funders (PSs

and/or third parties)

100% funding

100% funding

Broad non-prescriptive

topics, bottom-up

EDCTP priority-setting mechanisms

THREE-YEAR PLAN

• Short and medium

term priorities

• Estimated budgets

ANNUAL STRATEGIC

RESEARCH AGENDA

• Annually adjusted

priorities taking into

account EDCTP criteria

for prioritisation ANNUAL WORKPLAN • Planned calls for

proposals

• Participating States

Initiated Activities

(PSIAs)

• Detailed targets

STRATEGIC BUSINESS

PLAN

• Overall programme

strategy

• Scope of programme

• Funding mechanisms

• High-Level priorities

• Performance

evaluation

• Monitoring and

evaluation activities

Criteria for setting priorities

1

2

3

4

5

State of the product

development

landscape

For each disease area, these analyses identify the current

state of clinical development of interventions for

treatment, prevention and diagnosis.

Priority infections Analyses of disease burdens and changing patterns of

disease feed into priority setting for the poverty-related

infectious diseases targeted by EDCTP.

Disease burden and

treatment/prevention

priorities

These analyses identify key knowledge gaps and need for

new evidence.

Emerging

opportunities

Our expansion into new disease areas and into post-licensing

studies, including effectiveness studies, pharmacovigilance and

product-focused implementation research, provides new

opportunities for EDCTP to achieve impact

Balanced

portfolio

We aim to develop and sustain a balanced portfolio, across

disease areas, types of intervention and type of study,

balancing short-term and long-term priorities; this will help to

ensure steady flows through product development pipelines.

EDCTP supported activities

(#47)

African countries 1. Angola

2. Benin

3. Botswana

4. Burkina Faso

5. Cameroon

6. Central African Republic

7. Congo

8. Democratic Republic of Congo

9. Ethiopia

10. Gabon

11. The Gambia

12. Ghana

13. Guinea

14. Guinea-Bissau

15. Ivory Coast

16. Kenya

17. Liberia

18. Madagascar

19. Malawi

20. Mali

21. Mozambique

22. Namibia

23. Nigeria

24. Rwanda

25. Senegal

26. Sierra Leone

27. South Africa

28. Sudan

29. Tanzania

30. Uganda

31. Zambia

32. Zimbabwe

European countries 1. Belgium

2. Denmark

3. Finland

4. France

5. Germany

6. Ireland

7. Italy

8. Moldova

9. Netherlands

10. Norway

11. Portugal

12. Spain

13. Switzerland

14. Sweden

15. United Kingdom

French collaborations in

EDCTP projects

Researchers from

France collaborate with a

total of 14 European

countries and 28 sub-

Saharan African

countries in EDCTP

projects.

Cofunding contributions to EDCTP1 projects by

European country (cash via EDCTP)

European

Participating States

Total cofunding (cash

via EDCTP to

projects) (€)

EDCTP grant funding

received by PSs

institutions (€)

Net contribution from

PSs to EDCTP (€)*

Austria - 1,115,485 -1,115,485

Belgium 6,200 3,538,751 -3,532,551

Denmark 6,390,490 3,056,027 3,334,463

France - 2,162,418 -2,162,418

Germany - 8,896,550 -8,896,550

Greece - - -

Ireland 1,333,721 - 1,333,721

Italy - 742,795 -742,795

Luxembourg 98,103 - 98,103

Netherlands - 6,003,080 -6,003,080

Norway - - -

Portugal - - -

Spain 2,544,145 2,196,365 347,780

Sweden 9,591,885 3,254,178 6,337,707

Switzerland 1,123,765 1,047,751 76,014

United Kingdom 29,349,612 21,257,141 8,092,471

Total 50,437,921 53,270,540 -220,898

*based on cash received via EDCTP to projects


European country (cash and in-kind)

European


Total cofunding

(cash via EDCTP,

direct cash and in

kind to projects)

(€)

EDCTP grant

funding received by

PSs institutions (€)

Net contribution

from PSs to EDCTP

(€)

Austria 569,193 1,115,485 - 546,293

Belgium 10,829,119 3,538,751 7,290,367

Denmark 11,963,239 3,056,027 8,907,213

France 13,600,319 2,162,418 11,437,901

Germany 13,458,701 8,896,550 4,562,151

Greece - - -

Ireland 1,333,721 - 1,333,721

Italy 803,620 742,795 60,825

Luxembourg 606,102 - 606,103

Netherlands 12,103,800 6,003,080 6,100,720

Norway 3,642,000 - 3,642,000

Portugal - - -

Spain 5,158,287 2,196,365 2,961,922

Sweden 15,579,068 3,254,178 12,324,890

Switzerland 2,976,056 1,047,751 1,928,305

United Kingdom 46,460,708 21,257,141 25,203,567

Total 139,083,933 53,270,540 85,813,393


European country (cash received*)

European


Total cofunding

(cash received*) (€)

EDCTP grant

funding received by


Net contribution

from PSs to EDCTP

(€)**

Austria - - -

Denmark - 1,113,693 -1,113,693

Finland - 103,040 -103,040

France - 1,299,873 -1,299,873

Germany 2,075,000 742,000 1,333,000

Ireland 16,456 11,527 4,928

Italy - 183,338 -183,338

Luxembourg 1,990 - 1,990

Netherlands 234,237 3,798,462 -3,564,225

Norway 7,199 159,091 151,892

Portugal 200,000 - 200,000

Spain 811,449 436,408 375,041

Sweden 6,533,013 - 6,533,013

United Kingdom 19,173,698 20,484,587 -1,310,889

Total 29,053,042 28,332,020 721,022

*excluding cash committed

** based on cash received and not on the total commitment


European country (cash received and in-kind*)

European


Total cofunding

(cash received and in

kind)

(€)

EDCTP grant

funding received by


Net contribution

from PSs to EDCTP

(€)

Austria 1,019,014.25 - 1,019,014.25

Denmark 2,560,692 1,113,693 1,446,999

Finland 333,142 103,040 230,102

France 30,990,995 1,299,873 29,691,122

Germany 23,235,383 742,000 22,493,383

Ireland 4,953,600 11,527,75 4,942,072

Italy 1,760,000 183,338 1,576,662

Luxembourg 1,990 - 1,990

Netherlands 10,177,714 3,798,462 6,379,251

Norway 8,185,145 159,091 8,026,054

Portugal 779,928 - 779,928

Spain 6,144,024 436,408 5,707,616

Sweden 48,865,133 - 48,865,133

United Kingdom 181,259,635 20,484,587 160,775,047

Total 320,266,393 28,332,020 291,934,373

*In-kind represents PSIAs only and excludes administrative costs

EDCTP1 projects coordinated

by French Institutions

Name

coordinator

Project number Project title Institution in France Project value

(€)

E. Delaporte IP.2007.33011.004 A multicentre phase III trial of second-line

antiretroviral treatment in African adults

University of Montpellier

1

3,709,258.24

V. Leroy IP.2007.33011.002 International phase 2b randomized clinical

trial to assess two once-daily simplified

antiretroviral triple therapies among HIV

infected children early treated by a twice

daily triple therapy between 6 and 52

weeks of age and in virological success in

Africa: the MONOD Project

Victor Segalen Bordeaux 2

University

3,362,867.06

P. Van de

Perre

CT.2006.33020.004 A randomised controlled trial comparing

the efficacy of infant peri-exposure

prophylaxis with lopinavir/ritonavir (lpv/r)

versus lamivudine to prevent HIV-1

transmission by breastfeeding (PROMISE-

PEP trial)

Montpellier University

Hospital Centre (CHU)

11,669,298.40

P. Van de

Perre

SP.2011.41304.070 PROMoting Infant health and nutrition in

Sub-Saharan Africa – Evaluation of

InnovativeTuBerculosis diagnostic tests

(PROMISE-TB)



716,269.49

19,457,693.19

EDCTP2 projects coordinated

by French Institutions

Activity Reference Acronym Project title Name

Coordinator

Institution in

France

Project

value (€)

RIA DRIA2014-306 DiTECT-HAT Diagnostic tools for human

African trypanosomiasis

elimination and clinical trials

V. Lejon Institut de

Recherche pour le

Développement

(IRD)

2,999,006.25

Collaboration by French

Institutions in EDCTP1 projects

Project number Project title Institution in

France

Project

value (€)

CB.2005.41300.004 Training and Resources in Research Ethics Evaluation for Africa World Medical Association

362,016.41

CB.2005.41301.001 Establishing an African Coordinating Office for Ethics

University of Paris V - René

Descartes

60,658.65

CB.2005.41302.008 Strengthening the capacity of research ethics committees in Africa World Medical Association

50,881.00

CB.2007.41700.006

Establishment of the Central Africa Network on Tuberculosis, HIV/AIDS and Malaria for

the conduct of clinical trials (CANTAM)


Descartes

3,122,745.91

CB.2007.41700.009 TESA - Trials of Excellence in Southern Africa IRD

2,709,366.54

CB.2010.41302.008 Strengthening the Cameroon National Ethics Review Committee



63,957.76

CT.2004.31060.001

Evaluation of 4 artemisinin-based combinations for treating uncomplicated malaria in

African children Epicentre

5,551,862.71

CT.2006.33020.004

A randomised controlled trial comparing the efficacy of infant peri-exposure

prophylaxis with lopinavir/ritonavir (lpv/r) versus lamivudine to prevent HIV-1

transmission by breastfeeding (PROMISE-PEP trial)


Hospital Centre (CHU),

University of Montpellier 1,


Descartes

11,669,298.40

CT.2006.33111.001 African-European HIV Vaccine Development Network Sanofi-Aventis

3,233,156.25

CT.2006.33111.004 Feasibility of and capacity building for adolescent vaccine trials in South Africa

Victor Segalen Bordeaux 2

University

3,022,946.40

CT.2006.33111.013

Capacity development and strengthening in preparation for HIV vaccine trials in

Tanzania and Burkina Faso


Hospital Centre (CHU),

University of Montpellier 1

3,300,537.62

IP.2007.31060.002

An integrated approach to clinical trials, capacity building and networking in West

Africa. University of Lyon

9,253,627.12

IP.2007.31080.002

Evaluation of alternative antimalarial drugs to sulfadoxine-pyrimethamine for

intermittent preventive treatment in pregnancy (IPTp) in the context of insecticide

treated nets. IRD, Institut Pasteur

8,712,425.58



Project

number

Project title Institution in France Project

value (€) IP.2007.33011.002 International phase 2b randomized clinical trial to assess two once-daily simplified

antiretroviral triple therapies among HIV infected children early treated by a twice daily

triple therapy between 6 and 52 weeks of age and in virological success in Africa: the

MONOD Project

Montpellier University Hospital

Centre (CHU), University of

Paris V - René Descartes

3,362,867.06

IP.2007.33011.004 A multicentre phase III trial of second-line antiretroviral treatment in African adults ANRS, University Hospital

Saint-Antoine, University of

Montpellier 1

3,709,258.24

IP.2008.31060.003 Development of Fosmidomycin and Clindamycin, in a Fixed Dose Combination, for the

Treatment of Acute Uncomplicated Plasmodium falciparum Malaria

IRD 1,036,648.00

IP.2009.33011.009 A randomised controlled trial of 3 strategies for the treatment of ARV-naive HIV-infected

patients with tuberculosis (RAFA)

Tenon University Hospital 2,759,985.07

MF.2013.40205.018 Study of the prevalence and risk factors associated with Cryptococcus neoformans

complex in HIV-infected patients in Antananarivo, Madagascar

University Hospital of Grenoble 72,831.00

MS.2009.10800.003 Safety and efficacy of the universal use of the Efavirenz-Tenofovir-Emtricitabine and

Zidovudine-Lamivudine-Lopinavir/ritonavir combinations in pregnant and breastfeeding

women to prevent mother-to-child transmission of HIV-1 in resource-limited settings. A

multicentre randomized phase III clinical trial

INSERM, University of Paris V -

René Descartes, Victor Segalen

Bordeaux 2 University

801,850.70

MS.2009.10800.004 Assessment of the fixed-dose combination of Artesunate Mefloquine (ASMQ) as an

alternative antimalarial treatment for children in Africa

Cardinal Systems 3,134,507.38

MS.2010.10800.001 Fozivudine in Africa trials initiative (FATI) – a stepwise drug development programme for

an improved AZT treatment A cooperation with SME’s from DCs and built on an initiative

of the Global UNIDO Project "Strengthening the local production of essential generic

drugs in DCs”

INSERM, ANRS, University

Hospital Saint-Antoine 2,387,372.60

MS.2010.10800.002 Collaboration and integration of Tuberculosis Vaccine Trials in Europe and Africa (TBTEA) INSERM, Institut Pasteur,

French Research Institute for

International Development

10,571,174.48

NW.2005.10400.001 Strengthening laboratory capacity and nutrition skills in the context of an ICH-GCP clinical

trial for the prevention of mother-to-child transmission of HIV

French Research Institute for

International Development,

Montpellier University Hospital

Centre (CHU)

357,168.94



Project

number

Project title Institution in

France

Project value

(€) NW.2005.10401.002 Workshop on Tuberculosis Immune Reactivation Inflammatory Syndrome (TB IRIS) International Union

Against Tuberculosis

and Lung Disease (The

Union)

31,397.03

NW.2005.10403.001 Distance learning Master course in Clinical Trials Institut Pasteur 327,376.11

NW.2005.10403.003 African and European Network to establish a Masters Degree in Clinical Trials

Methodology for Africa



10,000.00

NW.2005.10403.004 Preparatory Consortium to initiate networking in Europe and Sub-Saharan Africa for the

establishment of a joint MSc in Clinical Research

Victor Segalen


10,000.00

NW.2005.10403.006 Distance learning masters course in clinical trials Institut Pasteur 5,878.28

NW.2005.10501.003 KIDS-ART-LINC: network of clinical centers treating HIV-infected children with

antiretroviral therapy in Africa to inform public health care and treatment programs

Victor Segalen


30,000.00

SP.2011.41304.021 Innovative approaches to diagnose and monitor patients with TB to facilitate conducting

clinical trials for the community-based treatment of MDR-TB

Institut de Genetique et

Microbiologie (IGEPE)

1,612,477.91

SP.2011.41304.070 PROMoting Infant health and nutrition in Sub-Saharan Africa – Evaluation of

InnovativeTuBerculosis diagnostic tests (PROMISE-TB)



716,269.49

TA.2005.40200.004 Randomized trial of the acceptability and efficacy of four drug regimens for seasonal

intermittent preventive treatment for malaria

IRD 196,226.00

TA.2005.40203.006 Identification of Plasmodium falciparum parasite virulence markers for the evaluation of

the impact of malaria control intervention according to the local parasite populations

Institute for Tropical

Medicine of the French

Army

96,047.00

TA.2010.40200.027 Optimization and standardization of the new functional antibody dependent respiratory

burst (ADRB) assay to evaluate anti-malarial immunity in endemic populations and

merozoite based vaccine candidates

Institut Pasteur 191,192.81

Grand total 82,534,008.45



Activity Reference Acronym Project title Name

Coordinator

Institution in

France

Project

value (€)

RIA DRIA2014-314 DREAMM Integrating the diagnosis and management of

HIV-associated central nervous system (CNS)

infections into routine health services in low

and middle income countries (LMICs)

Dr Angela Loyse Institut Pasteur

1,887,717.50

RIA DRIA2014-326 DIAMA Culture free diagnosis and follow-up of

multidrug resistant tuberculosis patients

Prof Dr Dissou

Affolabi

Genoscreen 2,967,202.50

RIA SRIA2015-1061 CAPRISA 018 CAPRISA 018: A randomised controlled trial to

assess the safety, acceptability and

pharmacokinetics of a sustained-release

tenofovir alafenamide sub-dermal implant for

HIV prevention in women

Professor Salim S.

Abdool Karim

Université Jean

Monnet, Saint-

Etienne

9,814,469.79

RIA TRIA2015-1092 AMBITION-cm High Dose AMBISOME on a Fluconazole

Backbone for Cryptococcal Meningitis

Induction Therapy in sub-Saharan Africa: A

Randomised Controlled Non-inferiority Trial

Dr Joseph Jarvis Institut Pasteur 9,990,712.00

CSA EDCTP-

Ethics2015-880

REECAO Renforcement de l'Ethique des Essais Cliniques

en Afrique de l'Ouest (REECAO)

Professor Ogobara

Doumbo

Universite

Catholique de Lyon

299,881.48

CSA EDCTP-

RegNet2015-

1045

CANTAM2 Central Africa clinical research Network –

CANTAM2 venture

Professor Francine

Ntoumi

IRD Not yet signed

CSA EDCTP-

RegNet2015-

1049

WANETAM West African Network for TB AIDS and Malaria Professor

Souleymane Mboup

IRD Not yet signed

CSA EDCTP-

RegNet2015-

1051

TESA II Trials of Excellence in Southern Africa II Dr Eusebio Macete European Clinical

Research

Infrastructure

Network (ECRIN-

ERIC)

Not yet signed

Collaborations in EDCTP

projects

Researchers from

France collaborate with a

total of 14 European

countries and 28 sub-

Saharan African

countries in EDCTP

projects.

EDCTP supported activities

(#47)


2. Benin

3. Botswana

4. Burkina Faso

5. Cameroon

6. Central African Republic

7. Congo

8. Democratic Republic of Congo

9. Ethiopia

10. Gabon

11. The Gambia

12. Ghana

13. Guinea

14. Guinea-Bissau

15. Ivory Coast

16. Kenya

17. Liberia

18. Madagascar

19. Malawi

20. Mali

21. Mozambique

22. Namibia

23. Nigeria

24. Rwanda

25. Senegal

26. Sierra Leone

27. South Africa

28. Sudan

29. Tanzania

30. Uganda

31. Zambia

32. Zimbabwe


2. Denmark

3. Finland

4. France

5. Germany

6. Ireland

7. Italy

8. Moldova

9. Netherlands

10. Norway

11. Portugal

12. Spain

13. Switzerland

14. Sweden

15. United Kingdom

EDCTP2 Networks

of Excellence


2. Botswana

3. Burkina Faso

4. Cameroon

5. Congo

6. Democratic Republic of the

Congo

7. Ethiopia

8. Gabon

9. Gambia

10. Ghana

11. Guinea-Bissau

12. Kenya

13. Malawi

14. Mali

15. Mozambique

16. Namibia

17. Nigeria

18. Rwanda

19. Senegal

20. South Africa

21. Sudan

22. Tanzania

23. Uganda

24. Zambia

25. Zimbabwe


2. France

3. Germany

4. Netherlands

5. Portugal

6. Spain

7. Sweden

8. Switzerland

9. United Kingdom

Congo

• Fondation Congolaise pour la Recherche

Médicale

Ethiopia

• Africa CDC

Gabon

• Centre de Recherches Médicales de

Lambaréné (CERMEL)

Ghana

• Noguchi Memorial Institute for Medical

Research (NMIMR)

• University of Ghana

• Kwame Nkrumah University of Science

and Technology (KNUST)

Nigeria

• Irrua Specialist Teaching Hospital

• Nigeria Center for Disease Control

Sierra Leone

• Mercy Hospital Research Laboratory

South Africa

• National Institute for Communicable

Diseases (NICD)

Sudan

• Institute of Endemic Diseases (IEND) -

University of Khartoum

• Emergency-Italy

Tanzania

• Southern African Centre for Infectious

Disease Surveillance

• National Institute for Medical Research -

Tanzania (NIMR)

• Ifakara Health Institute Trust (IHI)

• East, Central and Southern African

Health Community (ECSA-HC)

Uganda

• Uganda Virus Research Institute (UVRI)

Zambia

• University of Zambia (UNZA)

France

• Institut de Recherche pour le

Développement (IRD)

Germany

• Eberhard Karls Universitaet Tuebingen

• Bernhard-Nocht-Institut für

Tropenmedizin

• Institut für Virologie - Charité -

Universitätsmedizin Berlin

Italy

• National Institute for Infectious Diseases

Lazzaro Spallanzani

United Kingdom

• University College London (UCL)

• Royal Veterinary College University of

London

• Public Health England (PHE)

• Chatham House Centre on Global Health

Security

PANDORA-ID-NET Pan-African Network For Rapid Research,

Response, Relief and Preparedness for Infectious

Diseases Epidemics

ALERRT

African coaLition for Epidemic Research,

Response and Training

Cameroon

• Centre Pasteur du Cameroun

• University of Yaoundé

Central African Republic

• Institut Pasteur de Bangui - Central

African Republic

Cote d'Ivoire

• Institut Pasteur de Cote D’Ivoire

• Programme PACCI

The Democratic Republic of the Congo

• Ministry of Health - Democratic

Republic of the Congo

The Gambia

• Medical Research Council (MRC) Unit -

The Gambia

Ghana

• Kumasi Centre for Collaborative

Research in Tropical Medicine (KCCR)

Madagascar

• Institut Pasteur de Madagascar

Senegal

• Réseau Africain de Recherche sur le

SIDA/ Institut de Recherche en Santé, de

Surveillance Epidémiologique et de

Formations (RARS/IRESSEF)

Institut Pasteur de Dakar

Uganda

• Uganda Virus Research Institute (UVRI)

• MRC/UVRI Uganda Research Institute

on AIDS

Belgium

• Institute of Tropical Medicine

France

• Institut Pasteur

France

• The Alliance for International Medical

Action

• INSERM 1219, University of Bordeaux

• Université Paris Descartes

Germany

• Bernhard-Nocht-Institut für

Tropenmedizin

Switzerland

• UNDP/UNICEF/World Bank/WHO Special

Programme for Research and Training in

Tropical Diseases (TDR)

United Kingdom

• University of Oxford

• Imperial College of Science Technology

and Medicine

• London School of Hygiene and Tropical

Medicine (LSHTM)

2017 calls for proposals

Thank you

For more information:

www.edctp.org

Documents

EDCTP Programme Overview - Education.gouv.fr · • Established as a flagship European–Africa partnership and recognised international funder on clinical research for PRNIDs •